Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: Gene editing for the treatment of viral infections
Company stage: Pre-clinical
Diseases: HIV-1 infection/AIDS, progressive multifocal leukoencephalopathy (PML), Herpes simplex virus (HSV) infection, hepatitis B virus (HBV) infection
Genome editing tool: CRISPR-Cas9, CRISPR-CasX
Funding stage: Private
Location: San Francisco, CA, USA
Excsision BioTherapeutics is a start-up gene-editing company focused on curing viral infections with CRISPR. The company has developed a proprietary technolegy where dual gRNAs excise large sections of viral DNA, eliminating viral escape and reproduction. Its lead programme, EBT-101, is being developed to destroy the human immunodeficiency virus (HIV), to ultimately cure infection by the virus. Other programmes focus on eliminating viruses such as herpex simplex virus and hepatitis B virus.